Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2019-04-29 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
关于转让浙江赛尚医药科技有限公司67%股权的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by a company regarding the progress of a share transfer transaction involving Zhejiang Saishang Pharmaceutical Technology Co., Ltd. It details the history of the share transfer agreement, payment delays, legal actions taken, and current status of payments. The content focuses on the update of a capital transaction and related legal proceedings rather than a full financial report or earnings release. It is not a full annual or interim report, nor a call transcript or AGM material. The document is relatively short (1215 characters) and provides a status update on a financing-related matter (share transfer and payment collection). Therefore, it fits best under Capital/Financing Update (CAP).
2019-04-29 Chinese
审计报告
Regulatory Filings
2019-04-29 Chinese
非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告
Regulatory Filings
2019-04-29 Chinese
独立董事对公司对外担保情况及关联方占用资金情况的专项说明和独立意见
Audit Report / Information Classification · 95% confidence The document is a special statement and independent opinion by independent directors regarding the company's external guarantees and related party fund occupation, referencing regulatory notices from the China Securities Regulatory Commission. It discusses compliance with laws and internal controls but does not contain financial statements or detailed financial data. The document is a standalone audit-related opinion on specific regulatory compliance matters, not a full annual report or interim report. It is not a report publication announcement or a certification letter but a special audit-related statement. Therefore, it fits best under Audit Report / Information (AR). The document length is short but contains substantive content related to audit and compliance. FY 2018
2019-04-29 Chinese
关于上海傲源医疗用品有限公司原股东业绩承诺实现情况的专项审核报告
Regulatory Filings
2019-04-29 Chinese
东兴证券股份有限公司关于中源协和细胞基因工程股份有限公司发行股份购买资产并募集配套资金暨关联交易之2018年度业绩承诺实现情况的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed independent financial advisor's opinion on the fulfillment of a 2018 performance commitment related to a share issuance and asset purchase transaction by Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It includes references to a profit compensation agreement, audit reports, and specific financial performance targets for 2018, 2019, and 2020. The document is not a full annual report or audit report but rather a verification opinion on the achievement of performance commitments tied to a major asset restructuring and related party transaction. It is a specialized financial advisory opinion related to a capital transaction and performance guarantee. Given the content and context, this fits best under Capital/Financing Update (CAP) as it relates to issuance of shares for asset purchase and fundraising, and the verification of related performance commitments.
2019-04-29 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.